IXHL
Incannex Healthcare Inc.
$3.73
+1.63%
$44.6M
No data for this timeframe.
Vol
Market Cap$44.6M
Cap SizeNano Cap
Inst. Holders6 funds
Inst. Value$494.5K
Reddit Sentiment75° Bullish
SEC Reports9
Press Releases4
Recent Activity
Jun 10, 2026
SEC
Incannex Healthcare announced receipt of A$6.0M from the Australian R&D Tax Incentive program with an additional ~A$5.1M
PRESS-RELEASE — Impact 6/10
Jun 10, 2026
earnings
Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial Flexibility
In addition to the A$6.0 million refund received, the Company expects a further approximately A$5.1
Jun 10, 2026
SEC
Incannex Healthcare announced receipt of A$6.0 million (approximately US$4M) in R&D Tax Incentive refund from the Austra
8-K — Impact 5/10
Jun 9, 2026
SEC
Incannex Healthcare announced that Alliance Global Partners (AGP) has initiated equity research coverage with a BUY rati
8-K — Impact 3/10
May 14, 2026
Press
Incannex Healthcare announced the commencement of its DReAMzz clinical study for IHL-42X in obstructive sleep apnea, a c
Impact 6/10
Mar 27, 2026
Press
Incannex Healthcare has reactivated its share repurchase program, citing a disconnect between its current market valuati
Impact 4/10
Price Targets
$17.98
+382.0% upside
Strong Buy
Current $3.73
Low $17.98
Median $17.98
High $17.98
1 analysts
$17.98
$17.98
Analyst Ratings
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 8, 2026 | Alliance Global Partners | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.54 ▲ +36.1% | $-0.54 — $-0.54 | 98% YoY | 1 |
| Next Q | $-0.51 | $-0.51 — $-0.51 | 1 | |
| Current FY | $-2.48 | $-2.48 — $-2.48 | 1 | |
| Next FY | $-2.40 | $-2.40 — $-2.40 | 3% YoY | 1 |
Latest Reports
MIXED
PRESS-RELEASE
6/10
Incannex Healthcare announced receipt of A$6.0M from the Australian R&D Tax Incentive program with an additional ~A$5.1M
Jun 10, 2026
BULLISH
8-K
5/10
Incannex Healthcare announced receipt of A$6.0 million (approximately US$4M) in R&D Tax Incentive refund from the Austra
Jun 10, 2026
BULLISH
Press
6/10
Incannex Healthcare announced the commencement of its DReAMzz clinical study for IHL-42X in obstructive sleep apnea, a c
May 14, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| MIRAE ASSET GLOBAL ETFS | $449.6K | — |
| COMMONWEALTH EQUITY SERVICES, LLC | $36.3K | — |
| MORGAN STANLEY | $6.2K | — |
| BARCLAYS PLC | $2.3K | — |
| NATIONAL BANK OF CANADA | $135.00 | — |
Reddit Sentiment
75°
Bullish
Bearish
Neutral
Bullish
6 institutional holders with $494.5K total value (164,834 shares) as of 2026-Q1. Top holders: MIRAE, COMMONWEALTH, MORGAN.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 149,857 | $449.6K | 90.9% | — |
| 2 | COMMONWEALTH EQUITY SERVICES, LLC | 12,112 | $36.3K | 7.3% | — |
| 3 | MORGAN STANLEY | 2,065 | $6.2K | 1.3% | — |
| 4 | BARCLAYS PLC | 750 | $2.3K | 0.5% | — |
| 5 | NATIONAL BANK OF CANADA /FI/ | 45 | $135.00 | 0.0% | — |
| 6 | DANSKE BANK A/S | 5 | $15.00 | 0.0% | — |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
9 SEC filing reports analyzed. Sentiment: 3 bullish, 0 bearish, 1 mixed, 5 neutral. Avg impact: 4.1/10.
MIXED
PRESS-RELEASE
6/10
Incannex Healthcare announced receipt of A$6.0M from the Australian R&D Tax Incentive program with a
Jun 10, 2026
BULLISH
8-K
5/10
Incannex Healthcare announced receipt of A$6.0 million (approximately US$4M) in R&D Tax Incentive re
Jun 10, 2026
NEUTRAL
8-K
3/10
Incannex Healthcare announced that Alliance Global Partners (AGP) has initiated equity research cove
Jun 9, 2026
BULLISH
8-K
5/10
Incannex Healthcare announced the official commencement of its DReAMzz clinical study for IHL-42X in
May 14, 2026
NEUTRAL
8-K
2/10
Incannex Healthcare announced it won the 'Best New Technology Solution for Drug Development' award a
May 12, 2026
BULLISH
8-K
6/10
Incannex Healthcare announced that its PSX-001 oral synthetic psilocybin program aligns with a new W
Apr 22, 2026
NEUTRAL
8-K
3/10
Analysis based on filing metadata only — document content was unavailable. The 8-K filing for Incann
Mar 18, 2026
NEUTRAL
8-K
3/10
Analysis based on filing metadata only — document content was unavailable. The 8-K reports entry int
Mar 12, 2026
NEUTRAL
8-K
4/10
Analysis based on filing metadata only — document content was unavailable. The 8-K filing for Incann
Mar 12, 2026
BULLISH
6/10
Incannex Healthcare announced the commencement of its DReAMzz clinical study for IHL-42X in obstruct
May 14, 2026
NEUTRAL
4/10
Incannex Healthcare has reactivated its share repurchase program, citing a disconnect between its cu
Mar 27, 2026
NEUTRAL
3/10
Incannex Healthcare announced a partnership with the AASM Foundation to sponsor a grant for junior r
Mar 25, 2026
BULLISH
8/10
Incannex Healthcare announced statistically significant Phase 2 results for its lead drug candidate
Mar 12, 2026
Analyst Price Targets
$17.98 mean target
+382.0% upside
Strong Buy (1.00)
$17.98 Low
$17.98 High
| Metric | Value |
|---|---|
| Current Price | $3.73 |
| Target Low | $17.98 |
| Target Mean | $17.98 |
| Target Median | $17.98 |
| Target High | $17.98 |
| # Analysts | 1 |
| Recommendation | Strong Buy (1.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.54 | $-0.54 | $-0.54 | 97.7% | +36.1% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Next Q 2026-09-30 |
$-0.51 | $-0.51 | $-0.51 | — | — | — | $0.0B | 0.0% | 1 |
| Current FY 2026-06-30 |
$-2.48 | $-2.48 | $-2.48 | — | — | — | $0.0B | -100.0% | 1 |
| Next FY 2027-06-30 |
$-2.40 | $-2.40 | $-2.40 | 2.9% | — | — | $0.0B | 0.0% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.537 | |
| 7d ago | $-0.840 | +0.303 |
| 30d ago | $-0.840 | +0.303 |
| 60d ago | $-0.840 | +0.303 |
| 90d ago | $-0.840 | +0.303 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 8, 2026 | Alliance Global Partners | INITIATE | — | Buy |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
75°
Bullish
Bearish
Neutral
Bullish
4 mentions
4 bullish
0 bearish
4 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Jun 10, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Jun 10, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Jun 4, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Jun 3, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
$ixhl so heavy in here
▲ 1
💬 1
⚡ 0.5
$ixhl you ready?
▲ 1
💬 1
⚡ 0.5
Jun 10, 2026
earnings
Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial Flexibility
In addition to the A$6.0 million refund received, the Company expects a further approximately A$5.1 million in R&D Tax Incentive proceeds later this y
Jun 9, 2026
other
Incannex Announces Initiation of Research Coverage by Alliance Global Partners
<p>MELBOURNE, Australia and NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a cli
May 14, 2026
fda
Incannex Healthcare Officially Commences DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea
Major operational milestone achieved as Incannex advances late-stage development of IHL-42X, with all clinical sites identified and trial infrastructu
May 13, 2026
earnings_calendar
IXHL Q3 2026 Earnings Scheduled — 2026-05-13
Apr 1, 2026
Clinical Trial
Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis
Phase Phase 2 — TERMINATED
Mar 27, 2026
buyback
Incannex Reactivates Share Repurchase Program, Underscoring Confidence in Valuation and Strategic Position
Board initiates buyback activity following period of inactivity, with repurchases executed over the past two trading days <pre>Board initiates buyback
Mar 25, 2026
contract
Incannex Healthcare Announces Partnership with the AASM Foundation in Support of Sleep Apnea Research
Company Joins AASM Foundation Corporate Recognition Program and Sponsors Junior Investigator Research Grant as IHL-42X Advances Toward Potential Oral
Mar 12, 2026
other
Incannex Healthcare Inc. Announces Pricing of $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
<p align="justify">NEW YORK and MELBOURNE, Australia, March 12, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IHXL), ("Incannex" or the
Mar 12, 2026
fda
Incannex Strengthens Clinical Development Pathway for IHL-42X Following Positive Phase 2 Outcomes
Enhanced Phase 2 dose-optimization study designed to accelerate development and support a streamlined Phase 3 program <pre>Enhanced Phase 2 dose-optim